In this episode, A/Prof. Adrian Koh is joined by expert Prof. Timothy Lai direct from the APVRS congress to unpack the new and exciting 2-Year results from the SALWEEN trial. Discover how dual Ang-2/VEGF-A inhibition with Faricimab maintains vision gains, achieves sustained polyp regression, and enables extended dosing intervals up to Q20W in PCV patients.

In Episode 3, A/Prof. Adrian Koh and Prof. Gemmy Cheung discuss the evolving usage of combination therapy for PCV following the SALWEEN 1 Year results. They discuss how faricimab monotherapy is challenging the traditional reliance on PDT by offering significant polypoidal lesion closure rates and vascular stabilization through the dual-inhibition pathway.

In the second episode, A/Prof. Adrian Koh partners with A/Prof. Kelvin Teo to explore the advances in PCV diagnosis. The conversation navigates the complexities of multimodal imaging, from the diagnostic "gold standard" of ICG angiography to using OCT-A in routine monitoring. Furthermore, they explore the evolving criteria and real-world challenges in differentiating PCV from nAMD.

A/Prof. Adrian Koh is joined by leading expert Prof. Gemmy Cheung to dissect the critical 1-year results from the SALWEEN study. This podcast is a deep dive into the 1-year SALWEEN data readout, focusing on the implications for patients with PCV. The experts analyze the key clinical takeaways from the SALWEEN data, discussing its impact on clinical treatment paradigms for PCV patients.

[Coming Soon] Unpacking the Network Meta-Analysis for nAMD and DME

In this episode, A/Prof. Adrian Koh and Dr. Nancy Holekamp analyze the Network Meta-Analysis comparing Faricimab against Aflibercept 2mg and 8mg for nAMD and DME. This discussion explores how dual-pathway inhibition drives superior anatomical drying at week 12 and how these clinical insights are shaping real-world therapeutic strategies.

In this episode, A/Prof. Adrian Koh and A/Prof. SriniVas Sadda dive into the biomarkers of DME from the YOSEMITE/RHINE trials. They explore how faricimab’s dual inhibition mechanism offers superior clearance of hard exudates, inflammatory hyperreflective foci, and reduction in the development of epiretinal membranes.

For this episode, A/Prof. Adrian Koh is joined by A/Prof. Stela Vujosevic for an in-depth discussion on the evolving management of DME. Together, they explore how faricimab is redefining disease control in DME. The conversation unpacks key data from the YOSEMITE/RHINE and RHONE-X trials, highlighting robust visual outcomes, faster and deeper fluid resolution, and the potential for extended dosing intervals.